Amendment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A
Amendment No. 1

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2005
 
OR
 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
 
For the transition period from            to
 
Commission file number 0-17999

ImmunoGen, Inc.

Massachusetts
 
04-2726691
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices, including zip code)
 
(617) 995-2500
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ý  No  o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  ý  No  o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  o  No  ý 


Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Shares of common stock, par value $.01 per share: 41,077,428 shares outstanding as of November 4, 2005
 

EXPLANATORY NOTE

This Amendment No. 1 to the Form 10-Q for the quarterly period ended September 30, 2005 for ImmunoGen, Inc. is being filed solely for the purpose of filing corrected versions of Exhibits 31.1 and 31.2 in order to correct clerical omissions in each.
 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
ImmunoGen, Inc.
 
 
 
Date: November 16, 2005
By:
/s/ Mitchel Sayare
 
 
Mitchel Sayare
 
 
President and Chief Executive Officer
(principal executive officer)
 
 
 
Date: November 16, 2005
By:
/s/ Daniel M. Junius
 
 
Daniel M. Junius
 
 
Senior Vice President and Chief Financial Officer
(principal financial officer)
 
 
 
2